Categories: Health

Mesa Labs to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

 | Source: Mesa Laboratories, Inc.

LAKEWOOD, Colo., Dec. 18, 2025 (GLOBE NEWSWIRE) — Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced that Gary Owens, President and CEO, and John Sakys, CFO will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14th, 2026. Management will participate in a Formal Presentation at 4:30 p.m. Pacific Time.

A live webcast of the presentation will be accessible here and on the Events & Presentations section of Mesa Lab’s Investor Relations website at https://investors.mesalabs.com/. An archived replay of the webcast will be available through the same link following the presentation.

About Mesa Laboratories, Inc.

Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world.

For more information about Mesa, please visit its website at www.mesalabs.com.

Mesa Laboratories Contacts: 
Gary Owens; President and CEO,
John Sakys; CFO
1-303-987-8000
investors@mesalabs.com

GlobeNews Wire

Recent Posts

Thailand strengthens global confidence with safe and successful Jimmy Pelletier World Tour Stage 5

Landmark cross-country handcycle journey highlights Trusted Thailand initiative and affirms the Kingdom as a secure…

45 minutes ago

Commure Introduces Dictation: AI-Powered Clinical Voice, Now at the Cursor

MOUNTAIN VIEW, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Commure today announced Commure Dictation, a…

3 hours ago

Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium

April 02, 2026 08:00 ET  | Source: Tvardi Therapeutics HOUSTON, April 02, 2026 (GLOBE NEWSWIRE)…

3 hours ago

Provectus Biopharmaceuticals Highlights Preclinical Evidence of PV-10-Mediated Immune Modulation in Burn Wound Healing; Porcine Study Demonstrates Shift Toward Pro-Regenerative Tissue Environment

KNOXVILLE, Tenn., April 02, 2026 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”)…

3 hours ago

Wix Announces Preliminary Results of Modified Dutch Auction Tender Offer

NEW YORK, April 2, 2026—Wix.com Ltd. (Nasdaq: WIX) (“Wix” or the “Company”) today announced the…

4 hours ago

Aurora Mobile Unveils 500% Efficiency Boost Case Study at Tourism Web3 Summit 2026

SINGAPORE, April 02, 2026 (GLOBE NEWSWIRE) -- Aurora Mobile Limited (NASDAQ: JG) (“Aurora Mobile” or…

4 hours ago